SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-004841
Filing Date
2023-01-09
Accepted
2023-01-09 17:13:07
Documents
12
Period of Report
2023-01-05
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d399722d8k.htm   iXBRL 8-K 23569
  Complete submission text file 0001193125-23-004841.txt   142223

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA itci-20230105.xsd EX-101.SCH 2896
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE itci-20230105_lab.xml EX-101.LAB 17236
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE itci-20230105_pre.xml EX-101.PRE 10843
6 EXTRACTED XBRL INSTANCE DOCUMENT d399722d8k_htm.xml XML 3208
Mailing Address 430 EAST 29TH STREET NEW YORK NY 10016
Business Address 430 EAST 29TH STREET NEW YORK NY 10016 212-923-3344
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

IRS No.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36274 | Film No.: 23518863
SIC: 2834 Pharmaceutical Preparations